Fremont, Calif., devicemaker AngioScore has launched a 200 mm-long version of its AngioSculpt PTA Scoring Balloon Catheters for the treatment of above-the-knee peripheral artery disease.

The longer catheters are expected to be useful in treating the complex and lengthy lesions found in the upper leg — the most challenging femoro-popliteal lesions to treat, according to the company. The new catheters incorporate 200 mm balloons in diameters of 4.0, 5.0 and 6.0 mm with a novel scoring element specifically designed for these longer balloons.

The AngioSculpt catheters received FDA 510(k) clearance for the dilatation of lesions in the iliac, femoral, iliofemoral, popliteal, infra-popliteal and renal arteries, and to treat obstructive lesions of native or synthetic arteriovenous dialysis fistulae, the company said.

AngioScore recently became a wholly owned subsidiary of Spectranetics. The Colorado Springs maker of single-use devices for minimally invasive cardiovascular procedures completed its purchase of AngioScore for $230 million on June 30. — Kellen Owings

Subscribe to Devices & Diagnostics Letter for complete coverage of the medical devices industry. Click here for more information.